PSMA PET/CT for Staging and Treatment of Prostate Cancer

H&O What is prostate-specific membrane antigen (PSMA), and what makes it a good target for staging and treatment in prostate cancer? MH PSMA is a […]

Treatment Options for Patients With Prostate Cancer Who Develop Metastatic Disease After Hormonal Therapy

Case The patient is a 66-year-old man in good cardiovascular health. He has a family history of prostate cancer. He presents with fatigue and minor […]

New Approaches to Immunotherapy for Metastatic Castration-Resistant Prostate Cancer

H&O What are the benefits and limitations of sipuleucel-T in metastatic castration-resistant prostate cancer? SKS Sipuleucel-T (Provenge, Dendreon), which was the first therapeutic cancer vaccine […]

Adjuvant Therapy in High-Risk Prostate Cancer

Abstract: Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for significant cancer-related morbidity and mortality following […]

The Use of Multiparametric MRI in Diagnosis and Active Surveillance of Prostate Cancer

H&O When is multiparametric magnetic resonance imaging used in the diagnosis of prostate cancer? TP We have the option of using multiparametric magnetic resonance imaging […]

Bipolar Androgen Therapy in the Treatment of Prostate Cancer

H&O What is bipolar androgen therapy (BAT)? SD BAT consists of the administration of a high dose of androgen—also called testosterone—in an effort to control […]

First-Line Use of Novel Hormonal Agents in Prostate Cancer: A Critical Appraisal

Abstract: Castration has been the hallmark of the treatment of advanced prostate cancer for nearly a century. Conventional surgical or medical castration for the management […]

The Timing of Molecular Imaging in Prostate Cancer

H&O What molecular imaging techniques are available for use in prostate cancer? MM The US Food and Drug Administration (FDA) has approved 2 tracers for […]

Research in Drug Development for Advanced Prostate Cancer

H&O What are the standard approaches for the treatment of advanced prostate cancer? ME There are several treatments approved by the US Food and Drug […]

Prognostic and Therapeutic Implications of DNA Repair Gene Mutations in Advanced Prostate Cancer

Abstract: Recent work directed toward understanding the molecular features of advanced prostate cancers has revealed a relatively high incidence of both germline and somatic alterations […]

The Role of Genomics in Patients With Advanced Prostate Cancer

H&O What are the main technologic advances that have spurred on the current interest in genomics? MH The current interest in genomics was a downstream […]

Optimal Use of Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer

H&O What is the treatment protocol for patients with mCRPC? DG An exciting aspect of the field today is that there are many options for the […]

Prognostic and Predictive Biomarkers in Metastatic Castration-Resistant Prostate Cancer

H&O What are biomarkers in the context of metastatic castration-resistant prostate cancer (mCRPC)? AJA Biomarkers are any manifestation of a biological process, particularly in patients, […]

Circulating Tumor Cells in Prostate Cancer: Beyond Enumeration

Abstract: Circulating tumor cells (CTCs) are a population of rare cancer cells that have detached from the primary tumor and/or metastatic lesions and entered the […]

Prognostic Biomarkers in Early-Stage Prostate Cancer

H&O What is the traditional way for oncologists to determine prognosis in early-stage prostate cancer? EK The tools traditionally used to determine prognosis are the […]

Update on the Biology and Management of Neuroendocrine Prostate Cancer

H&O What is the definition of neuroendocrine prostate cancer (NEPC)? HB NEPC is an aggressive variant of prostate cancer that typically is diagnosed in the later stages […]

Current Understanding of Resistance to Abiraterone and Enzalutamide in Advanced Prostate Cancer

H&O How common is resistance to abiraterone and enzalutamide in castration-resistant prostate cancer (CRPC)? ESA Approximately 15% to 25% of patients with CRPC do not respond to […]